神经酰胺的功能及其在肺动脉高压中的作用

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (2): 267-271.

神经酰胺的功能及其在肺动脉高压中的作用

李发美, 余再新^*

中南大学湘雅医院心血管内科, 湖南长沙 410008

收稿日期:2020-08-28 修回日期:2020-11-06 出版日期:2021-02-05 发布日期:2021-01-19
通讯作者: ^*yuzaixin@126.com
基金资助:
国家自然科学基金(81873416)

Functions of ceramide and its role in pulmonary arterial hypertension

LI Fa-mei, YU Zai-xin^*

Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, China

Received:2020-08-28 Revised:2020-11-06 Online:2021-02-05 Published:2021-01-19
Contact: ^*yuzaixin@126.com

摘要/Abstract

摘要： 神经酰胺是一种鞘磷脂分子,作为细胞内第二信使,调控细胞增殖、分化、衰老和凋亡等生命活动。肺动脉高压是一类以肺小动脉重构和肺血管阻力增加为特征的疾病,神经酰胺通过介导肺血管重构、炎性反应过程和产生脂毒性参与肺动脉高压的发生、发展。了解神经酰胺的生物学功能及其参与肺动脉高压发生发展的具体机制,有助于给肺动脉高压的治疗提供新思路。

关键词: 神经酰胺, 合成与代谢, 生物学功能, 肺动脉高压

Abstract: Ceramide is a kind of sphingomyelin molecule,as a second messenger in cells,regulates cell proliferation,differentiation,senescence,apoptosis and other life activities.Pulmonary arterial hypertension is a disease characterized by pulmonary arterioles remodeling and increased increased vascular resistance. Ceramide is involved in the occurrence and development of pulmonary arterial hypertension by mediating pulmonary vascular remodeling,inflammatory response and lipotoxicity. Understanding the biological functions of ceramide and its mechanism involved in the development of pulmonary arterial hypertension may provide new idea for the treatment of pulmonary arterial hypertension.

Key words: ceramide, synthesis and metabolism, biological functions, pulmonary arterial hypertension

中图分类号:

李发美, 余再新. 神经酰胺的功能及其在肺动脉高压中的作用[J]. 基础医学与临床, 2021, 41(2): 267-271.

LI Fa-mei, YU Zai-xin. Functions of ceramide and its role in pulmonary arterial hypertension[J]. Basic & Clinical Medicine, 2021, 41(2): 267-271.

参考文献

[1] Garcia-gonzalez V, Diaz-villanueva JF, Galindo-hernandez O, et al. Ceramide metabolism balance, a multifaceted factor in critical steps of breast cancer development[J]. Int J Mol Sci, 2018, 19: 2527-2550.
[2] Leonardini A, D'oria R, Incalza MA, et al. GLP-1 receptor activation inhibits palmitate-induced apoptosis via ceramide in human cardiac progenitor cells[J]. J Clin Endocrinol Metab, 2017, 102: 4136-4147.
[3] Miller LG, Young JA, Ray SK, et al. Sphingosine toxicity in EAE and MS: evidence for ceramide generation via serine-palmitoyltransferase activation[J]. Neurochem Res, 2017, 42: 2755-2768.
[4] Hannun YA, Obeid LM. Sphingolipids and their meta-bolism in physiology and disease[J]. Nat Rev Mol Cell Biol, 2018, 19: 175-191.
[5] Ahn EH, Yang H, Hsieh CY, et al. Evaluation of chemotherapeutic and cancer-protective properties of sphingosine and C2-ceramide in a human breast stem cell derived carcinogenesis model[J]. Int J Oncol, 2019, 54: 655-664.
[6] 慕静静,曾耀英,黄秀艳,等. C2-神经酰胺对小鼠T淋巴细胞体外活化和增殖的影响[J]. 暨南大学学报 (医学版), 2009, 30: 133-138.
[7] Karsai G, Kraft F, Haag N, et al. DEGS1-associated aberrant sphingolipid metabolism impairs nervous system function in humans[J]. J Clin Invest, 2019, 129: 1229-1239.
[8] Chang YC, Fong Y, Tsai EM, et al. Exogenous C(8)-ceramide induces apoptosis by overproduction of ROS and the switch of superoxide dismutases SOD1 to SOD2 in human lung cancer cells[J]. Int J Mol Sci, 2018, 19: 3010-3022.
[9] NiaudetI C, Bonnaud S, Guillonneau M, et al. Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis[J]. Cell Signal, 2017, 33: 10-21.
[10] Mignard V, Dubois N, Lanoé D, et al. Sphingolipid distribution at mitochondria-associated membranes (MAMs) upon induction of apoptosis[J]. J Lipid Res, 2020, 61: 1025-1037.
[11] Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy[J]. Nat Rev Cancer, 2018, 18: 33-50.
[12] Scheiblich H, Schlutter A, Golenbock DT, et al. Activa-tion of the NLRP3 inflammasome in microglia: the role of ceramide[J]. J Neurochem, 2017, 143: 534-550.
[13] Albeituni S, Stiban J. Roles of ceramides and other sphingolipids in immune cell function and inflammation[J]. Adv Exp Med Biol, 2019, 1161: 169-191.
[14] Brittain EL, Talati M, Fessel JP, et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension[J]. Circulation, 2016, 133: 1936-1944.
[15] Granzotto A, Bomba M, Castelli V, et al. Inhibition of de novo ceramide biosynthesis affects aging phenotype in an in vitro model of neuronal senescence[J]. Aging (Albany NY), 2019, 11: 6336-6357.
[16] Talati M, Hemnes A. Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy[J]. Pulm Circ, 2015, 5: 269-278.
[17] Hemnes AR, Fessel JP, Chen X, et al. BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 318: L429-L1441.
[18] Pandolfi R, Barreira B, Moreno E, et al. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction[J]. Thorax, 2017, 72: 460-471.
[19] Andrieu G, Ledoux A, Branka S, et al. Sphingosine 1-phosphate signaling through its receptor S1P(5) promotes chromosome segregation and mitotic progression[J]. Sci Signal, 2017, 10:4007-4018.
[20] Macritchie N, Volpert G, Al washih M, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension[J]. Cell Signal, 2016, 28: 946-955.